-+ 0.00%
-+ 0.00%
-+ 0.00%
Xbrane Biopharma Gets Swedish Regulatory Nod for Drug Import, EU Sale
Share
Listen to the news
07:26 AM EST, 11/17/2026 (MT Newswires) -- The Swedish Medical Products Agency has authorized Xbrane Biopharma (XBRANE.ST) to import drugs from third-party suppliers outside the European Union or European Economic Area, according to a Tuesday release. The regulatory approval also allows the biopharmaceutical company to perform batch certification via a qualified person and subsequently distribute the medicinal products within the bloc. Xbrane said the clearance is expected to simplify its supply chain for Ximluci, its biosimilar to ranibizumab, and provide infrastructure for its daratumumab biosimilar candidate Xdarzane, as well as future products.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending